NCT03930602View on ClinicalTrials.gov

Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

May 27, 2019

Study Completion Date

May 27, 2019

Conditions
Healthy
Interventions
DRUG

BMS-986165

Participants will receive BMS-986165.

DRUG

Fluvoxamine

Participants will receive fluvoxamine.

Trial Locations (1)

84124

ICON Plc (PRA Health Sciences), Salt Lake City

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03930602 - Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165 | Biotech Hunter | Biotech Hunter